MUSCULAR DYSTROPHY

Antisense remains on track to positive clinical trial results

Finfeed Archived Mar 18, 2020

The recent completion of the monitoring phase of Antisense Therapeutics Limited's (ASX: ANP) ATL1102 Phase II Duchenne Muscular Dystrophy (DMD) trial remains on track for the end of March 2020.

Antisense appoints experienced biotech executive

Finfeed Archived Feb 28, 2020

Antisense Therapeutics Limited (ASX:ANP) has appointed Gil Price M.D. as Consultant Medical Director. Dr. Price is a clinical physician trained in internal medicine with a long-standing focus in drug development, adverse drug reactions, drug utilization and regulation.

ANP to Rapidly Advance to Phase IIb Trial After Dosing Results Exceed Expectations

Next Investors Archived Dec 19, 2019

One ASX biotech that is making progress in DMD therapy and hoping to shake up an industry set to be worth US$4 billion by 2023 is Antisense Therapeutics (ASX:ANP).

Breakthrough Prize given to Antisense pioneer

Finfeed Archived Oct 24, 2018

Last week, biopharmaceutical drug discovery and development company, Antisense Therapeutics (ASX:ANP) spiked 217% in one day

ASX Junior’s Flagship Immunomodulatory Drug Could Turn the Tide in Duchenne Muscular Dystrophy Treatment

Next Investors Archived Oct 16, 2018

Duchenne muscular dystrophy (DMD) is a rare, yet fatal, muscular genetic condition that affects one in 3600 to 6000 male births worldwide. This ASX junior, capped at just $7 million, is already in a Phase II clinical trial with its flagship drug to treat DMD.